Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02047981 · ClinicalTrials.gov registry record · Phase 4
Mortality Reduction After Oral Azithromycin: Mortality Study
A Phase 4 study of Childhood Mortality, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 4
- Development phase
- 190,238
- Enrollment target
- 6
- Study locations
NCT02047981 is a Phase 4 study of Childhood Mortality that has completed, run by University of California, San Francisco. The registered enrollment target is 190,238 participants. The trial reports 6 study locations across 3 states.
The verdict
NCT02047981, a Phase 4 study of Childhood Mortality, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 190,238 participants
- Enrollment target
- 6
- Study locations
Study Summary
Our long-term goal is to more precisely define the role of mass azithromycin treatments as an intervention for reducing childhood mortality. We propose a single multi-site (multi-country), cluster-randomized trial comparing communities randomized to oral azithromycin with those randomized to placebo. We hypothesize that mass azithromycin treatments will reduce childhood mortality.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Azithromycin
Study Locations (6)
Other
- College of Medicine at the University of Malawi, Blantyre - Blantyre
- The Carter Center, Niger - Niamey
- Kongwa Trachoma Project - Kongwa
- London School of Hygiene & Tropical Medicine - London
California
- UCSF Proctor Foundation - San Francisco
Maryland
- Johns Hopkins University - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 190,238 participants |
| Start Date | 2014-12 |
| Est. Completion | 2018-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02047981
The ClinicalTrials.gov registry entry for NCT02047981 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 190,238 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Childhood Mortality appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02047981 reports 6 study locations spanning 3 distinct geographic areas - top geographies include Other, California, Maryland.
Frequently Asked Questions
What is clinical trial NCT02047981 about?
NCT02047981 is a clinical study titled "Mortality Reduction After Oral Azithromycin: Mortality Study". Our long-term goal is to more precisely define the role of mass azithromycin treatments as an intervention for reducing childhood mortality. We propose a single multi-site (multi-country), cluster-randomized trial comparing communities randomized to oral azithromycin with those randomized to placebo...
What is the current status of trial NCT02047981?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 190,238 participants. The study started on 2014-12. Estimated completion is 2018-09.
What conditions does trial NCT02047981 study?
This clinical trial studies the following conditions: Childhood Mortality.
What interventions are being tested in trial NCT02047981?
The interventions under investigation include: Placebo (DRUG), Azithromycin (DRUG).
Who is sponsoring clinical trial NCT02047981?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02047981 being conducted?
This trial has 6 study locations across California, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.